Novartis To Launch Galvus In EU With Lower Dosing Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
EU approves DPP-4 inhibitor with label recommending 50 mg once or twice daily depending on type of combination therapy prescribed.